Research Analysts Offer Predictions for Myomo Q1 Earnings

Myomo, Inc. (NYSEAMERICAN:MYO) – Investment analysts at HC Wainwright raised their Q1 2025 EPS estimates for Myomo in a report issued on Wednesday, March 12th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings of ($0.09) per share for the quarter, up from their previous forecast of ($0.11). HC Wainwright has a “Buy” rating and a $9.50 price target on the stock. The consensus estimate for Myomo’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Myomo’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at ($0.13) EPS and FY2027 earnings at $0.20 EPS.

MYO has been the subject of several other research reports. Craig Hallum raised their price objective on Myomo from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, March 11th. Alliance Global Partners reissued a “buy” rating on shares of Myomo in a research report on Tuesday, March 11th. Finally, Ascendiant Capital Markets lifted their price target on Myomo from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $9.75.

Myomo Trading Down 2.4 %

NYSEAMERICAN:MYO opened at $5.31 on Monday. The firm has a market capitalization of $160.63 million, a P/E ratio of -23.09 and a beta of 1.68. Myomo has a twelve month low of $2.51 and a twelve month high of $7.17.

Institutional Investors Weigh In On Myomo

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AIGH Capital Management LLC grew its holdings in Myomo by 21.7% during the 4th quarter. AIGH Capital Management LLC now owns 3,381,567 shares of the company’s stock valued at $21,777,000 after buying an additional 602,719 shares in the last quarter. Soleus Capital Management L.P. purchased a new stake in Myomo during the 4th quarter valued at approximately $5,796,000. Portolan Capital Management LLC purchased a new stake in Myomo during the 4th quarter valued at approximately $2,446,000. Stonepine Capital Management LLC boosted its position in shares of Myomo by 174.4% during the 4th quarter. Stonepine Capital Management LLC now owns 274,426 shares of the company’s stock valued at $1,767,000 after acquiring an additional 174,426 shares during the last quarter. Finally, Manatuck Hill Partners LLC bought a new position in shares of Myomo during the 4th quarter valued at approximately $1,582,000. 44.99% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Thomas F. Kirk purchased 7,400 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was acquired at an average cost of $5.00 per share, for a total transaction of $37,000.00. Following the purchase, the director now directly owns 255,933 shares in the company, valued at $1,279,665. This trade represents a 2.98 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Micah Mitchell sold 48,000 shares of the business’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $5.16, for a total value of $247,680.00. Following the sale, the insider now owns 140,572 shares of the company’s stock, valued at approximately $725,351.52. This represents a 25.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.54% of the stock is owned by insiders.

Myomo Company Profile

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.